Navigation Links
Mitsubishi in Medical News

EnVivo and Mitsubishi Tanabe Enter License Agreement on EVP-6124 in Japan, Korea, Taiwan and Other Asian Countries

WATERTOWN, Mass., April 1, /PRNewswire/ -- EnVivo Pharmaceuticals today announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC) for the development and commercialization of its lead product candidate, EVP-6124, in Japan and several other Asian countries. EVP-6124 is EnVivo's ...

Medarex Announces Collaborative Research Agreement With Mitsubishi Pharma

Medarex, Inc. today announced a collaborative research agreement with Mitsubishi Pharma Corporation, a subsidiary of Mitsubishi Chemical Holdings Corporation . The two companies expect to generate and evaluate fully human monoclonal antibodies against a Mitsubishi target for the potential treatment...

BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company

..., in addition to potential milestone payments, from the sale of commercialization rights of telaprevir in Japan and other countries in the Far East to mitsubishi Tanabe Pharma Corporation, after announcing its intention to sell certain future European milestone payments for telaprevir aggregating $250 million e...

Dermatologic and Ophthalmic Drugs Advisory Committee Unanimously Recommends Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis

...or use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku Co., Ltd.) under the brand name TALION(R). TALION was co-developed by Tanabe Seiyaku and Ube Indus...

PATHFAST(R) Rapid Whole Blood Immunoassay Analyzer from Polymedco

...unce the introduction of the PATHFAST immunoassay analyzer, manufactured by mitsubishi Chemical Medience Corporation, Tokyo, Japan. The PATHFAST rapid point of c...and diagnostic kits to the medical market. PATHFAST is a registered mark of mitsubishi Chemical Medience Corporation, Tokyo, Japan. For more information, ple...

Quest Diagnostics Announces Pricing of Tender Offer for Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes

...Expiration Date. Quest Diagnostics has retained Banc of America Securities LLC to act as Lead Dealer Manager and Calyon Securities (USA) Inc. and mitsubishi UFJ Securities (USA), Inc. to serve as Co-Dealer Managers. Global Bondholder Services Corporation has been retained to serve as the depositary and as...

Quest Diagnostics Announces Early Tender Results of Offer to Purchase Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes

...xpiration Date. Quest Diagnostics has retained Banc of America Securities LLC to act as Lead Dealer Manager and Calyon Securities (USA) Inc. and mitsubishi UFJ Securities (USA), Inc. to serve as Co-Dealer Managers. Global Bondholder Services Corporation has been retained to serve as the depositary and th...

ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis

...or use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku Co., Ltd.) under the brand name TALION(R). TALION was co-developed by Tanabe Seiyaku and Ube Indus...

ProCure Treatment Centers to Equip Chicago Facility With Software Solutions From Elekta

...ns is in clinical use at more proton facilities than any other commercial vendor. Vendor-neutral, XiO also is used in conjunction with IBA, Varian and mitsubishi delivery systems. "Because of their proven track record, ease of use and commitment to future enhancements, ProCure selected the Elekta systems f...

Quest Diagnostics Commences Cash Tender Offer for Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes

...Expiration Date. Quest Diagnostics has retained Banc of America Securities LLC to act as Lead Dealer Manager and Calyon Securities (USA) Inc. and mitsubishi UFJ Securities (USA), Inc. to serve as Co-Dealer Managers. Global Bondholder Services Corporation has been retained to serve as the depositary and to ...
Mitsubishi in Medical Technology

SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

...-Plough will assume exclusive marketing rights outside the United States except in Japan, Indonesia and Taiwan, where golimumab will be co-marketed by mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical Kabushiki Kaisha; Hong Kong, where golimumab will be exclusively marketed by Janssen-Cilag; and C...

New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients

...-Plough will assume exclusive marketing rights outside the United States except in Japan, Indonesia and Taiwan, where SIMPONI will be co-marketed by mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical Kabushiki Kaisha; Hong Kong, where SIMPONI will be exclusively marketed by Janssen-Cilag; and Chi...

Two-Year Data Show Patients Receiving SIMPONI(TM) (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis

...ng-Plough will assume exclusive marketing rights outside the United States except in Japan, Indonesia and Taiwan, where SIMPONI will be co-marketed by mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical Kabushiki Kaisha; Hong Kong, where SIMPONI will be exclusively marketed by Janssen-Cilag; and Chi...

ISTA Pharmaceuticals Announces Positive Results for Phase IIb Study of Ecabet Sodium

...Senju Pharmaceuticals Co., Ltd., in November of 2004. Ecabet sodium is already marketed in Japan as an oral agent for gastric ulcers and gastritis by mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku Co., Ltd.) as an originator of ecabet sodium. Ecabet sodium represents a new class of molecule...

ISTA Pharmaceuticals' New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration

...or use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku Co., Ltd.) under the brand name TALION(R). TALION was co-developed by Tanabe Seiyaku and Ube Indus...

Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder

...inical targets are schizophrenia, anxiety and chronic pain. Complementing its own preclinical excellence R&D collaboration agreements were signed with mitsubishi Pharma Corporation (Japan) and Forest Laboratories in 2004 and 2005. The company has an original R&D portfolio with 17 ongoing projects including four...

ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing

...or use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku Co., Ltd.) under the brand name TALION(R). TALION was co-developed by Tanabe Seiyaku and Ube Indust...

Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis

... Schering-Plough has exclusive marketing rights outside the United States except in Japan, Indonesia and Taiwan where golimumab will be co-marketed by mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical Kabushiki Kaisha; Hong Kong, where golimumab will be exclusively marketed by Janssen-Cilag; and C...

New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of Ankylosing Spondylitis According to Phase 3 Study Findings

... Schering-Plough has exclusive marketing rights outside the United States except in Japan, Indonesia and Taiwan where golimumab will be co-marketed by mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical Kabushiki Kaisha; Hong Kong, where golimumab will be exclusively marketed by Janssen-Cilag; and C...

Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia

...inical targets are schizophrenia, anxiety and chronic pain. Complementing its own preclinical excellence R&D collaboration agreements were signed with mitsubishi Pharma Corporation (Japan) and Forest Laboratories in 2004 and 2005. The company has an original R&D portfolio with 16 ongoing projects including four...
Mitsubishi in Biological News

A happy new year for penguins

...troleum from southern Patagonia to Buenos Aires, coupled with expanding offshore oil drilling, have also loomed as growing threats in recent years. mitsubishi Corporation Foundation for the Americas has provided funding for the creation of this unique coastal protected area and for WCS's multi-faceted effort...

Urea tanks on diesel trucks -- that's the law in the United States starting in 2010

...0 centers in mid to late 2009 in a Sept. 29 news release. The Pilot Centers will also carry prepackaged DEF. Aqueous Urea Production Meanwhile, mitsubishi is increasing production of high-grade aqueous urea solution for urea SCR systems, according to GreenCarCongress.com. The company's plant at Kitakyush...

World's largest investor coalition seeks further disclosure on climate change and shareholder value

...tabase in the world on corporate climate change information. Investors that have signed up to CDP include Merrill Lynch, AXA, ANZ, Banco do Brazil, mitsubishi UFJ, AIG Investments, Barclays, RBS Group and HSBC. Legg Mason, Insurance Australia Group and the Florida State Board of Administration are among over...
Mitsubishi in Biological Technology

Odyssey Thera Announces Collaboration With Mitsubishi Tanabe Pharma Corporation, and Issuance of Core Patent in Japan

SAN RAMON, Calif., May 15 /PRNewswire/ -- Odyssey Thera, Inc. announced today the initiation of a collaboration with leading Japanese pharmaceutical company Mitsubishi Tanabe Pharma Corporation. The alliance involves the analysis of drug candidates from a number of Mitsubishi Tanabe preclinical p...

Cytochroma and Mitsubishi Tanabe form partnership for chronic kidney disease therapies in U.S. and Asia

MARKHAM, ON, and OSAKA, Japan, July 30 /PRNewswire/ - Cytochroma and Mitsubishi Tanabe Pharma Corporation ("MTPC") today announced that the companies have signed a license agreement under which Cytochroma granted MTPC an exclusive license in the U.S. and Asia, including Japan, to develop and c...

Quest Diagnostics Announces Final Tender Offer Results

...n June 18, 2009. Quest Diagnostics has retained Banc of America Securities LLC to act as Lead Dealer Manager and Calyon Securities (USA) Inc. and mitsubishi UFJ Securities (USA), Inc. to serve as Co-Dealer Managers. Global Bondholder Services Corporation has been retained to serve as the depositary and as...

Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

...ng-Plough will assume exclusive marketing rights outside the United States except in Japan, Indonesia and Taiwan, where SIMPONI will be co-marketed by mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical Kabushiki Kaisha; Hong Kong, where SIMPONI will be exclusively marketed by Janssen-Cilag; and Chi...

S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317

...th both Big Pharma and Biotech experience in the development and commercialization of oncology therapeutics. Its investors include: Domain Associates, mitsubishi International Corporation, Morganthaler Ventures, Oxford BioScience Partners and ProQuest Investments. More information about Tragara can be found at ...

BrainCells Inc. Appoints David E. Thompson to Its Board of Directors

...al stem cells, unlike an SSRI which acts by an indirect mechanism, which may eliminate serotonin associated side effects. BCI-540 was in-licensed from mitsubishi Pharma (MPC) based on its neurogenic properties and in previous studies was shown to be well tolerated in more than 900 subjects in Phase I and II cli...

ISTA Pharmaceuticals Files New Drug Application with U.S. FDA for Bepreve(TM)

...or use as a systemic drug in the treatment of allergic rhinitis and urticaria/pruritus in July 2000 and January 2002, respectively, and is marketed by mitsubishi Tanabe Pharma Corporation (formerly Tanabe Seiyaku Co., Ltd.) under the brand name TALION(R). TALION was co-developed by Tanabe Seiyaku and Ube Indust...

Yale professor T.P. Ma awarded the Connecticut Medal of Technology

...s companies worldwide, including IBM, Intel, Motorola, Lucent Technology, GE, Hughes, Rockwell Semiconductors, Philips, Siemens, Hitachi, Toshiba, and mitsubishi Electric. Ma is a patent holder, co-editor of a book, and contributor to several book chapters as well as over 180 research papers. He is a member ...

One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study

... Schering-Plough has exclusive marketing rights outside the United States except in Japan, Indonesia and Taiwan where golimumab will be co-marketed by mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical Kabushiki Kaisha; Hong Kong, where golimumab will be exclusively marketed by Janssen-Cilag; and C...

MacroGenics Raises $25M in Series D-2 Financing

...nd Eli Lilly and Company. Also participating in the financing were existing investors Alexandria Real Estate, Alta Partners, CIDC, InterWest Partners, mitsubishi UFJ, OrbiMed Advisors, Red Abbey Venture Partners, RiverVest, Texas Pacific Group Ventures and Ventures West. MacroGenics expects to use the proceed...
Mitsubishi in Biological Products

Analog thermal printer, Mitsubishi (115/230V) for BioDoc-It and VisiDoc-It Imaging Systems from UVP

Description: Conveniently document gels, films and membranes with a high quality thermal printer. Compact, footprint printer Supplies 256 gray scale for high resolution, archive-quality thermal film prints Process low-cost prints in seconds ...
Company:UVP

Analog thermal printer, Mitsubishi (115V) for all UVP imaging systems except BioDoc-It and VisiDoc-It from UVP

Description: Conveniently document gels, films and membranes with a high quality thermal printer. Compact, footprint printer Supplies 256 gray scale for high resolution, archive-quality thermal film prints Process low-cost prints in seconds ...
Company:UVP
Other Tags
(Date:4/17/2015)... Canadian, Oklahoma (PRWEB) April 17, 2015 ... and Drug Dependence (NCADD) notes that drinking and driving ... attention. At the same time, the link between ... such as domestic abuse and violence and sexual assault, ... , According to the NCADD, 5.3 million adults in ...
(Date:4/17/2015)... “We have seen healing, a lot of healing, and a ... Shawn Kafader of Friendship Village. “People have found purpose. ... contribute have created beautiful pieces of art.” For the past ... that was launched to benefit residents of the retirement community. ... Art Institute in Chicago, worked as an intern at Friendship ...
(Date:4/17/2015)... In Defense of Christians (IDC) Executive Director ... April 15th, the European Parliament joined its voice with ... Armenian Genocide, “paying tribute, on the eve of the ... Armenian victims who perished in the Ottoman Empire.” ... this timely and needed recognition of a tragic episode ...
(Date:4/17/2015)... 17, 2015 Representatives Jim Himes (D-CT) ... Treatment Act HR 1849 in congress on April 16, ... treatment for patients with the genetic disease. , ... would be the first to create a federally led ... of hereditary hemorrhagic telangiectasia. This would effectively prevent premature ...
(Date:4/17/2015)... California (PRWEB) April 17, 2015 As ... above in his new offering of platelet-rich plasma ... Sports Medicine (MOSM) is known for its world-class ... Meier brings extensive surgical experience lacking in many other ... stem cell treatments are utilized for pain management and ...
Breaking Medicine News(10 mins):Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 3Health News:Healing At Friendship Village Due To Art Therapy 2Health News:In Defense of Christians Condemns Armenian Genocide 2Health News:In Defense of Christians Condemns Armenian Genocide 3Health News:House Representatives Introduce Bill to Fight Genetic Disease 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report ... markets for Iris Biometrics in US$ Thousands. The report provides ... , Japan , Europe ... , and Latin America . ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
Other Contents